There are particularly unique limitations in lung cancer, where beyond suppressive forces due to pathologic tumor vasculature and metabolic as well as immunologic mediators of CD8+ T cell inhibition, distinct challenges limit viable immune-cell engagement with the tumor cell membrane. The gene discussed is CD8A; the disease is lung carcinoma.